Mammotome Launches the First Vacuum-Assisted Breast Biopsy System Designed for Lesion Excision

August 17, 2022

image of Mammotome Revolve™ EX

Mammotome Launches the First Vacuum-Assisted Breast Biopsy System Designed for Lesion Excision

CINCINNATI, OHIO – August 17, 2022 – Mammotome, a global leader in breast care and the pioneer of vacuum-assisted breast biopsy, is pleased to introduce the Mammotome Revolve™ EX Dual Vacuum-Assisted Breast Biopsy System. This is the first vacuum-assisted biopsy device designed specifically for the excision of benign breast lesions and is twice as fast as traditional vacuum-assisted breast biopsy systems. The Mammotome Revolve™ EX device is a minimally invasive solution and enables physicians to provide better care for patients with benign lesions by avoiding the risks and trauma of an open surgical procedure and creating little to no scarring.

The Mammotome Revolve™ EX Biopsy System introduces several features to make the user experience faster and more intuitive. An expanded collection cup provides greater storage capacity and an option to inspect a single specimen, giving the clinician optimized flexibility for collecting, separating and identifying lesions. The enhanced sample collection cup also eliminates the need to change the probe between samples, providing efficiency and cost savings. Unlike other devices on the market, the Mammotome Revolve™ EX Biopsy System has an optional custom EZ-Sleeve™ sterile cover tailored to the device, creating a more sanitary procedure while reducing the procedure turnaround time and labor requirements. An innovative tip protector release system enables safe handpiece placement with just one hand before and during the procedure, and the on-demand variable aperture provides flexibility and minimizes the excision of undesired tissue.

In addition, the Mammotome Revolve™ EX Biopsy System is two times faster than the original Mammotome® EX and the Mammotome Revolve™ U/S Dual Vacuum-Assisted Breast Biopsy Systems. The ergonomic and lightweight handpiece design allows the physician to reach and control the device throughout the procedure comfortably. “What is very important about the Mammotome Revolve™ EX System for us, as surgeons and radiologists, is that it is two times faster than other systems,” said Prof. Dawid Murawa, Chief of the Clinic of General Surgery and Surgical Oncology, University Hospital in Zielona Gora in Poland, “and that it is very comfortable to operate, for example, when we remove a bigger benign lesion.”

Since the invention of vacuum-assisted breast biopsy in 1995, Mammotome has continued to focus on delivering cutting-edge breast care solutions designed to meet clinicians’ needs and the individual needs of their patients.

“We are thrilled to provide clinicians with the very first vacuum-assisted biopsy system designed explicitly for benign lesion excision,” said Michael Feld, President of Mammotome. “Mammotome is focused on being an indispensable partner to physicians, clinicians and patients across the globe and the launch of the new Mammotome Revolve™ EX system reinforces our standing as an innovator in the breast care space.”

Media Contact: Erica Bednar, Director of Marketing Communications

Phone: 513-391-4737

[email protected]

About Mammotome

At Mammotome, our passion is providing innovative breast care technologies that create efficiency, while never forgetting that at the heart of every breast cancer journey is a patient. Through our ever-expanding portfolio of Mammotome breast biopsy products and Neoprobe and Sentimag® lesion localization systems, we strive to improve the patient’s journey and achieve better outcomes. For more information, visit and follow Mammotome on social media (Facebook, LinkedIn, Twitter, Instagram, YouTube).


©2022 Devicor Medical Products, Inc. Mammotome and Mammotome Revolve are registered trademarks of Devicor Medical Products, Inc., in the USA and optionally in other countries. Other logos, product and/or company names might be trademarks of their respective owners. MDM 220489 REV 8/22